| Literature DB >> 35260749 |
David Martín-Hernández1,2, Irene L Gutiérrez3,4, Marta González-Prieto3,4, Karina S MacDowell3,4, Javier Robledo-Montaña3,4, Hiram Tendilla-Beltrán4,5, Natalia Calleja-Rodríguez3,4, Álvaro G Bris3,4, Cristina Ulecia-Morón3,4, Beatriz Moreno3,4, Javier R Caso3,4, Borja García-Bueno3,4, Sandra Rodrigues-Mascarenhas4,6, Ignacio Marín-Jiménez7, Juan Carlos Leza3,4, Luis Menchén7,8.
Abstract
The chronic inflammatory process that characterizes inflammatory bowel diseases (IBD) is mainly driven by T-cell response to microbial and environmental antigens. Psychological stress is a potential trigger of clinical flares of IBD, and sphingosine-1-phosphate (S1P) is involved in T-cell recruitment. Hence, stress impact and the absence of sphingosine kinase 2 (Sphk2), an enzyme of S1P metabolism, were evaluated in the colon of mice after sub-chronic stress exposure. Here, we show that sub-chronic stress increased S1P in the mouse colon, possibly due to a decrease in its degradation enzymes and Sphk2. S1P accumulation could lead to inflammation and immune dysregulation reflected by upregulation of toll-like receptor 4 (TLR4) pathway, inhibition of anti-inflammatory mechanisms, cytokine-expression profile towards a T-helper lymphocyte 17 (Th17) polarization, plasmacytosis, decrease in IgA+ lymphoid lineage cells (CD45+)/B cells/plasmablasts, and increase in IgM+ B cells. Stress also enhanced intestinal permeability. Sphk2 knockout mice presented a cytokine-expression profile towards a boosted Th17 response, lower expression of claudin 3,4,7,8, and structural abnormalities in the colon. Intestinal pathophysiology should consider stress and S1P as modulators of the immune response. S1P-based drugs, including Sphk2 potentiation, represent a promising approach to treat IBD.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35260749 PMCID: PMC8904788 DOI: 10.1038/s41598-022-08011-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1General stress effects and S1P pathways analyses in the colon of WT and Sphk2 mice after sub-chronic stress exposure. Percentage of weight gain after the stress protocol (a), plasma corticosterone levels (b), relative spleen weight (c), colon S1P levels (d), Sphk1 mRNA levels (e), Sphk2 mRNA levels (f), SGPL1 mRNA levels (g), SGPP1 mRNA levels (h), SGPP2 mRNA levels (i), S1PR1 mRNA levels (j), S1PR2 mRNA levels (k), S1PR3 protein expression (l). Data are means ± SEM of 5–8 mice per group. The densitometric data of the respective bands of interest are normalized by β-actin (lower band). Blots were cropped (black lines) to improve the clarity and conciseness of the presentation. Two-way ANOVA considering stress (S) and Sphk2−/− as independent variables followed by Tukey's post hoc for (a–l); *S p < 0.05, **S p < 0.01, ***S p < 0.001; #Sphk2−/− p < 0.05; @ (interaction) p < 0.05; +p < 0.05, ++p < 0.01 vs Control WT; &p < 0.05 vs Control Sphk2−/−. Two-tailed Student t-test for f; %%p < 0.01. Sphk2: sphingosine kinase 2; WT: wild-type; Sphk2−/−: Sphk2 knockout; S1P: sphingosine-1-phosphate; Sphk1: sphingosine kinase 1; SGPL1: sphingosine-1-phosphate lyase 1; SGPP1: sphingosine-1-phosphate phosphatase 1; SGPP2 sphingosine-1-phosphate phosphatase 2; S1PR1: sphingosine-1-phosphate receptor 1; S1PR2: sphingosine-1-phosphate receptor 2; S1PR3: sphingosine-1-phosphate receptor 3.
Figure 2Inflammatory evaluation, TLR4 pathway expression, and anti-inflammatory mechanisms in the colon of WT and Sphk2−/− mice after sub-chronic stress exposure. H&E staining of 10 µm descending colon sections: individual qualitative evaluation (1–4) of parameters related to inflammation: severity, extent, hyperplasia, goblet cell loss, cryptitis, crypt abscesses, erosion, ulceration, granulation tissue, irregular crypts, crypt loss, and villous blunting (a), overall inflammatory score (1–4) (b), and representative images of each group (c), TLR4 protein expression (d), p-p38 protein expression (e), iNOS protein expression (f), LOX-15 mRNA levels (g), and LXRβ mRNA levels (h). For a and b, data are means of two sections per mice and 5–8 mice per group. For d–h, data are means ± SEM of 5–8 mice per group. The densitometric data of the respective bands of interest are normalized by β-actin (lower band). Blots were cropped (black lines) to improve the clarity and conciseness of the presentation. Two-way ANOVA considering stress (S) and Sphk2−/− as independent variables followed by Tukey's post hoc; **S p < 0.01, ***S p < 0.001; @ (interaction) p < 0.05; +p < 0.05, ++p < 0.01 vs Control WT; &p < 0.05, &&p < 0.01 vs Control Sphk2−/−. Sphk2: sphingosine kinase 2; WT: wild-type; Sphk2−/−: Sphk2 knockout; TLR4: toll-like receptor 4; p-p38: phospho mitogen-activated protein kinase (MAPK) p38; iNOS: inducible nitric oxide synthase; 15-LOX: 15-lipoxygenase; LXRβ: Liver X receptor β.
Figure 3mRNA cytokine expression in the colon of WT and Sphk2−/− mice after sub-chronic stress exposure. mRNA levels of CX3CL1 (a), OSM (b), IL-1β (c) IL-10 (d), IL-12a (e), IL-12b (f), IL-17a (g), IL-22 (h), IL-23 (i), and IL-33 (j). Data are means ± SEM of 5–8 mice per group. Two-way ANOVA considering stress (S) and Sphk2−/− as independent variables followed by Tukey's post hoc; *S p < 0.05, **S p < 0.01, ***S p < 0.001; #Sphk2−/− p < 0.05, ##Sphk2−/− p < 0.01; +p < 0.05, ++p < 0.01, +++p < 0.001 vs Control WT; &p < 0.05, &&&p < 0.001 vs Control Sphk2−/−; $p < 0.05 vs Stress WT. Sphk2: sphingosine kinase 2; WT: wild-type; Sphk2−/−: Sphk2 knockout; CX3CL1: fractalkine; OSM: oncostatin M; IL: interleukin.
Figure 4Flow cytometry analysis of B cell differentiation in the colon of WT and Sphk2−/− mice after sub-chronic stress exposure. Representative dot plots showing the gating strategy used to distinguish lymphoid lineage cells (CD45+), B cells (CD45+B220+CD138−/low), plasmablasts (CD45+B220−CD138−/low), and plasma cells (CD45+B220−CD138high). Considering the total number of CD45+ cells as 100%, percentage of B cells (a), plasmablasts (b), and plasma cells (c) were plotted. Data are means ± SEM of 5–8 mice per group. Two-way ANOVA considering stress (S) and Sphk2−/− as independent variables followed by Tukey's post hoc; *S p < 0.05, **S p < 0.01. Sphk2: Sphingosine kinase 2; WT: wild-type; Sphk2−/−: Sphk2 knockout.
Figure 5Flow cytometry analysis of IgA and IgM positive cells in different colon immune populations of WT and Sphk2−/− mice after stress exposure. Representative dot plots showing the gating strategy used to distinguish IgA−IgM−, IgA+IgM−, IgA−IgM+, and IgA+IgM+ in each cell population. Percentage of IgA+CD45+ (a), IgA+ B cells (b), IgA+ plasmablasts (c), IgA+ plasma cells (d), IgM+CD45+ (e), IgM+ B cells (f), IgM+ plasmablasts (g), IgM+ plasma cells (h) were plotted. Data are means ± SEM of 5–8 mice per group. Two-way ANOVA considering stress (S) and Sphk2−/− as independent variables followed by Tukey's post hoc; *S p < 0.05, **S p < 0.01, ***S p < 0.001; @ (interaction) p < 0.05; +p < 0.05, ++p < 0.01 vs Control WT; &p < 0.05, &&&p < 0.001 vs Control Sphk2−/−. Sphk2: Sphingosine kinase 2; WT: wild-type; Sphk2−/−: Sphk2 knockout; Ig: immunoglobulin.
Figure 6Intestinal permeability analyses and expression levels of structural proteins in the colon of WT and Sphk2−/− mice after sub-chronic stress exposure. Representative transmission electron micrographs of colonic tight junctions (TJs) in epithelial cells of each group (a), quantification of TJs (b), and FITC-D4000 detected in plasma (c), ZO-1 protein expression (d), ZO-1 mRNA levels (e), Cldn2 mRNA levels (f), Cldn3 mRNA levels (g), Cldn4 mRNA levels (h), Cldn5 mRNA levels (i), Cldn7 mRNA levels (j), Cldn8 mRNA levels (k). For b, data are means ± SEM of 66–168 TJs per group. Arrows indicate TJ ultrastructure. For c-k, data are means ± SEM of 5–8 mice per group. The densitometric data of the respective bands of interest are normalized by β-actin (lower band). Blots were cropped (black lines) to improve the clarity and conciseness of the presentation. Two-way ANOVA considering stress (S) and Sphk2−/− as independent variables followed by Tukey's post hoc; *S p < 0.05, **S p < 0.01, ***S p < 0.001; #Sphk2−/− p < 0.05, ##Sphk2−/− p < 0.01; @ (interaction) p < 0.05, @@ p < 0.01; +p < 0.05, ++p < 0.01, +++p < 0.001 vs Control WT; &p < 0.05, &&p < 0.01, &&&p < 0.001 vs Control Sphk2−/−; $p < 0.05, $$p < 0.01 vs Stress WT. Sphk2: sphingosine kinase 2; WT: wild-type; Sphk2−/−: Sphk2 knockout; TJ: tight junction; FITC-D4000: FITC-dextran average molecular weight 4000; ZO-1: zonula occludens-1; Cldn: claudin.
Figure 7Graphical abstract. The upper part of the image illustrates the sub-chronic stress effects on wild-type (WT) mice. The lower part describes the sub-chronic stress effects on Sphk2 knockout (Sphk2−/−) mice. The black arrows represent the stress effects, and the red arrows the Sphk2 deletion effects. The figure was prepared using the Motifolio Illustration Toolkits (https://motifolio.com) (Motifolio Inc., Ellicott City, MD, USA) and edited with Microsoft PowerPoint 365 (Microsoft Corporation, Redmond, WA, USA). WT: wild-type; Sphk2−/−: Sphk2 knockout; FITC-D4000 (F): fluorescein isothiocyanate-dextran average MW 4,000; S1P: sphingosine-1-phosphate; Sphk1: sphingosine kinase 1; Sphk2: sphingosine kinase 2; SGPL1: sphingosine-1-phosphate lyase 1; SGPP1: sphingosine-1-phosphate phosphatase 1; SGPP2 sphingosine-1-phosphate phosphatase 2; S1PR: sphingosine-1-phosphate receptor; TLR4: Toll-like receptor 4; p-p38: phospho mitogen-activated protein kinase (MAPK) p38; iNOS: inducible nitric oxide synthase; 15-LOX: 15-lipoxygenase; LXRβ: Liver X Receptor β; ZO-1: zonula occludens-1.; Cldn: claudin; CX3CL1: (C-X3-C motif) chemokine ligand 1 (fractalkine); OSM: oncostatin M; IL: interleukin; Th17: T-helper lymphocyte 17; Ig: immunoglobulin.
Two-way ANOVA analyses (F values and dfs).
| Parameter | Stress | Sphk2−/− | Interaction |
|---|---|---|---|
| %weight increase | F(1,21) = 0.4230; p = 0.5225 | F(1,21) = 0.4073; p = 0.5303 | |
| Corticosterone | F(1,21) = 0.08156; p = 0.7780 | F(1,21) = 1.301; p = 0.2668 | |
| %spleen weight | F(1,22) = 0.2001; p = 0.6590 | F(1,22) = 0.06906; p = 0.7952 | |
| S1P | F(1,21) = 1.151; p = 0.2955 | F(1,21) = 0.1854; p = 0.6711 | |
| Sphk1 | F(1,22) = 1.654; p = 0.2118 | F(1,22) = 0.2767; p = 0.6041 | F(1,22) = 0.1868; p = 0.6698 |
| Sphk2 | - | - | - |
| SGPL1 | F(1,22) = 2.132; p = 0.1584 | F(1,22) = 2.012e-008; p = 0.9999 | |
| SGPP1 | F(1,22) = 2.572; p = 0.1230 | F(1,22) = 0.5859; p = 0.4521 | |
| SGPP2 | F(1,22) = 1.797; p = 0.1937 | ||
| S1PR1 | F(1,22) = 1.699; p = 0.2059 | F(1,22) = 0.7525; p = 0.3951 | F(1,22) = 3.340; p = 0.0812 |
| S1PR2 | F(1,22) = 0.04937; p = 0.8262 | F(1,22) = 0.02840; p = 0.8677 | |
| S1PR3 | F(1,20) = 0.002192; p = 0.9631 | ||
| TLR4 | F(1,21) = 2.439; p = 0.1333 | F(1,21) = 1.328; p = 0.2621 | |
| p-p38 | F(1,22) = 0.1634; p = 0.6900 | F(1,22) = 0.1343; p = 0.7175 | |
| INOS | F(1,20) = 0.2215; p = 0.6430 | F(1,20) = 0.1586; p = 0.6947 | |
| 15-LOX | F(1,21) = 0.004723; p = 0.9459 | F(1,21) = 0.001169; p = 0.9730 | |
| LXRβ | F(1,22) = 2.936; p = 0.1007 | F(1,22) = 2.237; p = 0.1490 | |
| CX3CL1 | F(1,21) = 2.375; p = 0.1382 | F(1,21) = 1.961; p = 0.1760 | |
| OSM | F(1,22) = 1.595; p = 0.2199 | ||
| IL-1β | F(1,21) = 0.02637; p = 0.8725 | F(1,21) = 0.004779; p = 0.9455 | |
| IL-10 | F(1,21) = 0.01580; p = 0.9012 | F(1,21) = 0.3324; p = 0.5703 | |
| IL-12a | F(1,21) = 0.07968; p = 0.7805 | F(1,21) = 0.004024; p = 0.9500 | |
| IL-12b | F(1,22) = 0.9311; p = 0.3451 | F(1,22) = 0.1147; p = 0.7380 | |
| IL-17a | F(1,22) = 0.06996; p = 0.7939 | ||
| IL-22 | F(1,21) = 1.114; p = 0.3033 | ||
| IL-23 | F(1,22) = 0.4412; p = 0.5135 | ||
| IL-33 | F(1,21) = 0.1867; p = 0.6700 | ||
| % B cells/CD45+ | F(1,20) = 2.801; p = 0.1098 | F(1,20) = 1.281; p = 0.2711 | F(1,20) = 0.4127; p = 0.5279 |
| % plasmablasts/CD45+ | F(1,21) = 0.2110; p = 0.6507 | F(1,21) = 0.01597; p = 0.9006 | |
| % Plasma cells/CD45+ | F(1,18) = 0.1133; p = 0.7403 | F(1,18) = 0.02198; p = 0.8838 | |
| % IgA+CD45+ | F(1,19) = 0.05343; p = 0.8197 | F(1,19) = 0.3688; p = 0.5508 | |
| % IgA+ B cells | F(1,21) = 1.630; p = 0.2156 | F(1,21) = 0.2720; p = 0.6074 | |
| % IgA+ plasmablasts | F(1,19) = 0.5317; p = 0.4748 | F(1,19) = 0.1750; p = 0.6804 | |
| % IgA+ plasma cells | F(1,19) = 0.4779; p = 0.4977 | F(1,19) = 2.227; p = 0.1521 | F(1,19) = 1.493; p = 0.2367 |
| % IgM+CD45+ | F(1,20) = 0.1023; p = 0.7524 | F(1,20) = 0.3953; p = 0.5367 | F(1,20) = 0.004599; p = 0.9466 |
| % IgM+ B cells | F(1,20) = 1.312; P = 0.2655 | F(1,20) = 0.1618; P = 0.6917 | |
| % IgM+ plasmablasts | F(1,20) = 0.002136; p = 0.9636 | F(1,20) = 0.01444; P = 0.9055 | F(1,20) = 0.2722; P = 0.6076 |
| % IgM+ plasma cells | F(1,20) = 1.212; p = 0.2840 | F(1,20) = 0.4073; p = 0.5306 | |
| Colon TJ openings | F(1,452) = 0.4204; p = 0.5171 | F(1,452) = 0.4936; p = 0.4827 | |
| FITC-D4000 | F(1,21) = 1.622; p = 0.2167 | F(1,21) = 5.075e-005; p = 0.9944 | |
| ZO-1 WB | F(1,21) = 3.570; p = 0.0727 | F(1,21) = 0.3328; p = 0.5701 | |
| ZO-1 mRNA | F(1,22) = 3.167; p = 0.0889 | ||
| Cldn2 | F(1,21) = 0.8661; p = 0.3626 | F(1,21) = 0.05279; p = 0.8205 | F(1,21) = 2.044; p = 0.1676 |
| Cldn3 | F(1,22) = 0.05430; p = 0.8179 | F(1,22) = 0.01108; p = 0.9171 | |
| Cldn4 | F(1,22) = 3.001; p = 0.0972 | ||
| Cldn5 | F(1,21) = 1.941; p = 0.1781 | ||
| Cldn7 | F(1,22) = 0.04552;p = 0.8330 | ||
| Cldn8 | F(1,22) = 2.838; p = 0.1062 |
Statistically significant values (p < 0.05) are in bold.